After years of demands from shareholders for another major deal, Gilead has made a spectacular move, sealing a deal to acquire cell therapy leader Kite for just under $12 billion. Gilead had been ...

Gilead has completed its $11.9 billion landmark acquisition of Kite Pharma, as the pharma switches focus from hepatitis C to cancer and revolutionary CAR-T therapies. The California-based pharma ...

Kite Pharma is flying high with the addition of a new member to its senior leadership team. Brian Heath has joined Gilead Sciences’ cell therapy subsidiary as a senior vice president and head of ...